Navigation Links
Major EPSRC Programme Grant to support new Oxford Centre for Drug Delivery Devices
Date:5/23/2014

Cancer therapy drugs tend to achieve limited accumulation and poor penetration in tumours, reducing their effectiveness. For many years, the only methods used to improve drug uptake by tumours have been pharmacological, and these have had limited success.

Recent research at Oxford University has shown that physical mechanisms triggered by ultrasound, magnetic fields or shock waves can dramatically improve the delivery and penetration of existing and experimental drugs into tumours.

Now a new research centre, The Oxford Centre for Drug Delivery Devices (OxCD3), will look to exploit engineering approaches, involving a combination of stimulus- responsive nanocarriers and medical devices already in clinical use, to improve the therapeutic outcomes of drug-based cancer treatments.

The new centre will be based at the University of Oxford and has been made possible by a 10.1 million Programme Grant which includes 6.4 million from the Engineering and Physical Sciences Research Council (EPSRC).

Led by Professors Coussios, Stride, Carlisle and Cleveland in the Institute of Biomedical Engineering, OxCD3 represents a partnership between the Department of Engineering Science, the Department of Oncology (Professors Seymour, Sibson and Vallis), the MRC Weatherall Institute of Molecular Medicine (Prof. Rabbitts), the Nuffield Department of Surgical Science (Prof. Friend) and the Clinical Biomanufacturing Facility (Dr Moyle).

The principal investigator, Professor Constantin Coussios, said: "We are very grateful to EPSRC, our industrial partners and the University of Oxford for their support of OxCD3. This will enable the creation of a sustainable, world-‐ unique multi-‐disciplinary environment for combinational engineering of biology, chemistry and medical devices to improve drug delivery under a single roof. It is also expected to create a much-‐needed training environment for the next generation of young scientists working on combination therapies and biomedical nanotechnology, by providing direct exposure to regulatory and manufacturing issues encountered when translating laboratory research into production and clinical practice."

The new Centre will initially focus on improving the delivery of several classes of cancer drugs, ranging from conventional chemotherapy and radiopharmaceuticals to next-‐generation antibodies, viruses and siRNA, from proof-of-concept laboratory studies to manufacture in preparation for clinical trials. The ultimate aim is to establish a centre of excellence for challenging drug delivery applications across a broad range of biological barriers and disease indications beyond cancer.


'/>"/>

Contact: EPSRC Press Office
pressoffice@epsrc.ac.uk
01-793-444-404
Engineering and Physical Sciences Research Council
Source:Eurekalert

Related medicine news :

1. Therapy sought to reduce major risk from minor bleeding that can follow stroke
2. Major lung resection safer than ever, especially at the busiest hospitals
3. Genetic alterations in shared biological pathways as major risk factor for ASD
4. Gen X obesity a major problem for healthcare, workforce
5. Surgery after major stroke also improves survival odds in elderly patients
6. A majority prefers letting computers decide
7. Major third-hand smoke compound causes DNA damage -- and potentially cancer
8. Patient requests for specific drugs have major impact on prescribing, reports study in Medical Care
9. Major League Baseball players win more games following Tommy John surgery
10. NYU researchers find majority of Latinas are unaware of their risk of diabetes
11. International study shows majority of children unaware of cigarette warning labels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Mass. (PRWEB) , ... February 23, 2017 , ... ... as an approved content provider for the National Institute for Health and ... and social care-related organizations in the National Health Service (NHS) to search, order ...
(Date:2/23/2017)... ... 2017 , ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice ... a 2017 Top Patient Rated Henderson Dentist by Find Local Doctors earlier ... physicians and dentists who have earned high ratings and superior patient reviews from multiple ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global ... announced that Premier Research, a leading clinical development service provider, has selected ERT’s ... increasingly complex, due in part to an array of circumstances including the use ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... the pre-eminent publication and community for those in the fight against cancer, has ... important in their success. HRA will release top-line findings in a webinar, ...
(Date:2/23/2017)... ... ... perfect opportunity for the nation to come together to combine ... bracket – with its favorite fruit – apples! To celebrate ... lovers to join the “Apple Madness” bracket tournament – a ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Australien, 24. Februar 2017 ITL ... Unternehmen des Gesundheitsbereiches, ist erfreut, für das zum ... dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. ... Aktualisierung zum Wachstum" finden Sie hier . ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)...  The particle counters market is projected to ... 275.9 million in 2016, at a CAGR of ... http://www.reportlinker.com/p04718602-summary/view-report.html The growing pharmaceutical and ... growth in manufacturing industries in emerging nations are ... counters. On the other hand, technical limitations of ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
Breaking Medicine Technology: